At Regen Med Meeting, Cardio3, Others Grapple With Complex Market
At the recent European Advanced Therapies Investor Day in London, pharma and medtech attendees touted the need for open minds and innovative approaches to developing cell therapies.
You may also be interested in...
A clear sign the regenerative medicine and therapy market is making considerable progress comes from the amount of investor funding pouring into the space, and although a lot of the technology is still spoken about in the future tense, a variety of new companies are bringing the future much closer. An additional hallmark of the market is the role device companies are finding for themselves in an industry primarily lead by pharmaceutical businesses.
Eventually, someone is going to have clinical and commercial success with a personalized cancer therapy. Learning from the mistakes of Dendreon and others, Argos Therapeutics expects to be first, and automation is its key.
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.